Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15560693 | 0.92 | ILK (0.74) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17077279 | 0.91 | ILK (0.66) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17085051 | 0.91 | ILK (0.51) | ILKPTGS1EPHX2PTGS2ALOX5 | |
| SCHEMBL17077241 | 0.90 | ILK (0.62) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17077237 | 0.89 | ILK (0.62) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17077272 | 0.89 | ILK (0.61) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17077268 | 0.88 | ILK (0.62) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL19839523 | 0.88 | ILK (0.68) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL17077280 | 0.88 | ILK (0.62) | ILKPTGS1EPHX2PTGS2AKR1C3 | |
| SCHEMBL9105969 | 0.87 | ILK (0.67) | ILKPTGS1EPHX2PTGS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9457031-B2 | Antibacterial protein kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2016-10-04 | — | — | US | disclosed |
| US-9457031-B2 | Antibacterial protein kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2016-10-04 | — | — | US | disclosed |
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2015-09-17 | — | — | US | disclosed |
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | DMPK, MYLK3, MYLK2 | ILK 1625/4885PTGS1 192/4885EPHX2 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.